The EOC Uroboard, a multidisciplinary approach to the management of patients with urogenital cancer

Author(s)
C.Azinwi Ngwa(1,2), F.Stoffel(3), B.Mazzola(3), P.Peyer(3), A.Llado(2), C.Puligheddu(4), S.Crippa(5), A.Bordoni(5), V.Bianchi(5), B.Marongiu(2,6), M.Pascale(2,6), E.Roggero(2,6), A.Richetti(1,2), R.Wyttenbach(4), G.Pesce(1,2)

Institution(s)
(1)Radiotherapy and (2)Medical Oncology IOSI, (3)Urology and (4)Radiology, EOC, Bellinzona, (5)Pathology and Cancer Registry, Locarno, and (6)International Prostate Research Group

Objective
The need of a Tumour Board(TB) for urogenital tumors(UT) at Ente Ospedaliero Cantonale(EOC) derives from the necessity to offer patients(pts) a treatment strategy agreed by the relevant specialists. The gain in knowledge and capability guarantee accurate diagnosis and pondered treatment indication

Materials
Pts with UT were evaluated within the EOC hospitals by this TB via videoconference. In each meeting urologists, radiation and medical oncologists, radiologists and pathologists were present. For each case medical history, imaging, pathology report and slides were evaluated. A specific treatment strategy or diagnostic indication was then formulated

Results
A total of 220 cases of UT(191 M, 29 F) were discussed from Oct 2010 to Dec 2012. Histology were: 94(43%) prostate, 51(23%) bladder, 50(23%) kidney and 25(11%) testis. After creation of the TB, the percentage of cases discussed at initial diagnosis rose from 14.5% in the first half of 2011 to 20.45% in the second half of 2012, and an increased enrolment rate in clinical trials was observed

Conclusion
The Uroboard guarantees a better definition of tailored treatment strategy for urogenital cancer pts, contributes to the updating of tumour-specific guidelines and increases motivation for enrolment in clinical trials